MTCO2P22

Across TCGA pan-cancer cohorts, MTCO2P22 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MTCO2P22’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where MTCO2P22 RNA is repressed in tumor relative to normal tissue. In most cancer types MTCO2P22 is over-expressed in tumor, although a few such as PAAD and LIHC show the opposite, repressed pattern.

PAAD, KICH, and UCEC are the cancer types where MTCO2P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCO2P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PAAD	All	All	−1.052	<.001	6	view →
KICH	Female	All	+0.797	.005	3	view →
UCEC	All	IV	+0.199	.006	2	view →
LUAD	Male	III,IV	+0.328	.026	1	view →
LIHC	Male	II,III,IV	−0.288	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MTCO2P22–PAAD

Open the PAAD breakdown →